Consensus Collegium Pharmaceutical, Inc. BOERSE MUENCHEN

Stocks

354 US19459J1043

Pharmaceuticals

Market Closed - BOERSE MUENCHEN Other stock markets 16:43:40 2026-07-17 EDT			5-day change	1st Jan Change
31.40 ^EUR	-1.26%		+1.29%	-25.24%

05-15	Collegium Pharmaceutical, Inc. Announces Appointment of Michael Donovan as Director	CI
05-12	Collegium completes acquisition of Azstarys® from Corium Therapeutics	RE

Evolution of the Average Target: Collegium Pharmaceutical, Inc.

Evolution of the Target Price: Collegium Pharmaceutical, Inc.

Changes in Analyst Recommendations: Collegium Pharmaceutical, Inc.

33cb6f29f446dcb8e58abbc640b3d2e.HmMdpYvYOrdJZo9Ob-gzBAl4ao0ZnYTKNO-iut8UrQ8.WRRC79ngcc8LX8V-I5xhQmEgEv0t6dO6Rbbl_Ys5-mFyBWzU2bFPzzxUwg~2996e403bd9f0bb1702c10bbb0d3ab24

Analysts' recommendations: Collegium Pharmaceutical, Inc.

02-10	Truist Adjusts Price Target on Collegium Pharmaceutical to $58 From $55, Maintains Buy Rating	MT
01-07	Truist Securities Adjusts Price Target on Collegium Pharmaceutical to $55 From $48, Maintains Buy Rating	MT
12-09	Barclays Initiates Collegium Pharmaceutical at Overweight With $58 Price Target	MT
11-07	Truist Raises Price Target on Collegium Pharmaceutical to $48 From $45, Keeps Buy Rating	MT
25-08-08	Truist Raises Price Target on Collegium Pharmaceutical to $45 From $42, Keeps Buy Rating	MT
25-08-07	Collegium Pharma Q2 revenue beats analyst expectations	RE
25-01-10	Needham Upgrades Collegium Pharmaceutical to Buy From Hold, Price Target is $46	MT
24-08-09	Truist Securities Adjusts Price Target on Collegium Pharmaceutical to $42 From $40, Maintains Buy Rating	MT
24-07-30	HC Wainwright Upgrades Collegium Pharmaceutical to Buy From Neutral, Price Target is $47	MT
24-06-07	Jefferies Upgrades Collegium Pharmaceutical to Buy From Hold, Adjusts Price Target to $44 From $41	MT
24-05-10	Needham Downgrades Collegium Pharmaceutical to Hold From Buy	MT
24-05-10	Piper Downgrades Collegium Pharmaceutical to Neutral From Overweight, Price Target at $39	MT
24-02-26	Piper Sandler Adjusts Price Target on Collegium Pharmaceutical to $39 From $37, Maintains Overweight Rating	MT
24-02-26	Truist Adjusts Price Target on Collegium Pharmaceutical to $40 From $37, Maintains Buy Rating	MT
24-01-04	Truist Adjusts Collegium Pharmaceutical's Price Target to $37 From $31, Keeps Buy Rating	MT
24-01-04	Jefferies Downgrades Collegium Pharmaceutical to Hold From Buy, Raises Price Target to $37 From $30	MT
23-08-25	Needham Adjusts Price Target on Collegium Pharmaceutical to $36 From $35, Maintains Buy Rating	MT
23-05-02	Jefferies Assumes Collegium Pharmaceutical at Buy With $30 Price Target	MT
23-01-05	Needham Adjusts Price Target on Collegium Pharmaceutical to $35 From $34, Maintains Buy Rating	MT
22-11-04	Needham Adjusts Price Target on Collegium Pharmaceutical to $34 From $36, Maintains Buy Rating	MT
22-08-08	HC Wainwright Downgrades Collegium Pharmaceutical to Neutral From Buy	MT
22-04-06	Needham Adjusts Collegium Pharmaceutical's Price Target to $36 From $34, Keeps Buy Rating	MT
22-02-22	Piper Sandler Adjusts Collegium Pharmaceutical's Price Target to $42 From $36, Reiterates Overweight Rating	MT
22-02-15	Needham Adjusts Collegium Pharmaceutical's Price Target to $34 From $28, Reiterates Buy Rating	MT
22-02-15	HC Wainwright Adjusts Collegium Pharmaceutical's Price Target to $29 From $26, Reiterates Buy Rating	MT

More recommendations

Sector Comparison:

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	ELI LILLY AND COMPANY					+7.74%
	JOHNSON & JOHNSON					+6.68%
	ABBVIE INC.					+4.75%
	ROCHE HOLDING AG					+7.49%
	NOVARTIS AG					-1.48%
	ASTRAZENECA PLC					+25.19%
	NOVO NORDISK A/S					-4.34%
	AMGEN INC.					-2.64%
	GILEAD SCIENCES, INC.					+17.89%
	Average					+6.81%
	Weighted average by Cap.					+6.86%